Medigus, Ltd. MDGS – News Alert:
We've got more fresh news hitting the wires this morning from MDGS. One of the things we like best about the company is the frequency with which it communicates with its shareholders.
Today's release pertains to the hiring of an advisory firm to guide Polyrizon, in which Medigus is a stakeholder, toward FDA approval for its nasal gels which are preventative against viruses, including COVID-19 and the flu.
Tel Aviv, Israel, Oct. 22, 2021 (GLOBE NEWSWIRE) --
Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, announced today that Polyrizon Ltd., (37.01%), that it has engaged with a full-service Contract Research Organisation (CRO), to advise the Company in its pursuit of Food and Drug Administration (FDA) submission for its products. (>>View Full PR
We typically encourage our readers to keep track of not only the featured items in our daily reports, but our 'Extended Watchlists' as well. They often include hidden opportunities waiting to be unearthed.
Such was the case yesterday with DWAC, which was included in our premarket report
before exploding from a daily low of 12.62 up as high as 52.00. That works out to an intraday run of 312% Our overall observed range has increased already this morning with a premarket high of 93.43, which marks a rise of 640%
We also signaled MGTI on Monday morning
, and it has posted a solid intraweek performance thus far. The stock came up from a low of .041 to a high of .064, an increase of 58%
Last but not least, we went three for three on options ideas in yesterday's report, which provided the following intraday gain opportunities for our readers:
CSX Weekly $34-36 Calls
BX Weekly $130-133 Calls
T Weekly $25.50-26.50 Calls
Fresh Options Ideas:
STX Weekly $82.50-85 Calls
AXP Weekly $177.50-182.50 Calls
PHUN, CRTD, GROM, DATS, CZNI, SEGI, TONR, ASTI, NSAV, CIVX, CAGC